^
    over2years
    A Clinical Study of CAR-T Treating Relapsed or Refractory T Cell Lymphoblastic Acute Leukemia/ Lymphoma (clinicaltrials.gov)
    P1/2, N=30, Active, not recruiting, Guangzhou Bio-gene Technology Co., Ltd | Recruiting --> Active, not recruiting | Initiation date: Aug 2023 --> May 2023
    Enrollment closed • Trial initiation date
    |
    CD7 (CD7 Molecule)
    |
    CD7 CAR-T
    over2years
    A Clinical Study of CAR-T Treating Relapsed or Refractory T Cell Lymphoblastic Acute Leukemia/ Lymphoma (clinicaltrials.gov)
    P1/2, N=30, Recruiting, Guangzhou Bio-gene Technology Co., Ltd | Phase classification: P=N/A --> P1/2
    Phase classification
    |
    CD7 (CD7 Molecule)
    |
    CD7 CAR-T
    over2years
    A Clinical Study of CAR-T Treating Relapsed or Refractory T Cell Lymphoblastic Acute Leukemia/ Lymphoma (clinicaltrials.gov)
    P1/2, N=30, Recruiting, Guangzhou Bio-gene Technology Co., Ltd | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CD7 (CD7 Molecule)
    |
    CD7 CAR-T
    over2years
    A Clinical Study of CAR-T Treating Relapsed or Refractory T Cell Lymphoblastic Acute Leukemia/ Lymphoma (clinicaltrials.gov)
    P=N/A, N=30, Not yet recruiting, Guangzhou Bio-gene Technology Co., Ltd
    New P1/2 trial • New trial
    |
    CD7 (CD7 Molecule)
    |
    CD7 CAR-T